US-based biotech Abcuro has raised $200m to advance the development of its monoclonal antibody ulviprubart in the rare muscle disease called inclusion body myositis (IBM). The funding round ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback